Cite
Shimada E, Endo M, Matsumoto Y, et al. Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?. J Clin Med. 2021;10(21)doi: 10.3390/jcm10214972.
Shimada, E., Endo, M., Matsumoto, Y., Tsuchihashi, K., Ito, M., Kusaba, H., Nabeshima, A., Nawata, T., Maekawa, A., Matsunobu, T., Setsu, N., Fujiwara, T., Iida, K., Nakagawa, M., Hirose, T., Kanahori, M., Oyama, R., Isobe, T., Ariyama, H., Kohashi, K., Yamamoto, H., Oda, Y., Iwamoto, Y., Akashi, K., Baba, E., & Nakashima, Y. (2021). Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?. Journal of clinical medicine, 10(21), . https://doi.org/10.3390/jcm10214972
Shimada, Eijiro, et al. "Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?." Journal of clinical medicine vol. 10,21 (2021). doi: https://doi.org/10.3390/jcm10214972
Shimada E, Endo M, Matsumoto Y, Tsuchihashi K, Ito M, Kusaba H, Nabeshima A, Nawata T, Maekawa A, Matsunobu T, Setsu N, Fujiwara T, Iida K, Nakagawa M, Hirose T, Kanahori M, Oyama R, Isobe T, Ariyama H, Kohashi K, Yamamoto H, Oda Y, Iwamoto Y, Akashi K, Baba E, Nakashima Y. Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?. J Clin Med. 2021 Oct 26;10(21). doi: 10.3390/jcm10214972. PMID: 34768491; PMCID: PMC8584915.
Copy
Download .nbib